Skip to main content
    I

    Intellia Therapeutics Inc (NTLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.86
    +0.16 (+1.65%)

    Market Cap: $1.36B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Intellia Therapeutics Inc (NTLA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Intellia Therapeutics (NTLA) to earn -$3.27 per share in the fiscal year ending Dec 31, 2026, on revenue of $43.32M. Of 20 analysts, 10 rate the stock Buy or Strong Buy, 6 Hold and 4 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 6 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 20 ratings average 2.75, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.

    RatingAnalystsShare
    Strong Buy15.0%
    Buy945.0%
    Hold630.0%
    Sell210.0%
    Strong Sell210.0%
    Consensus
    Hold
    Total analysts
    20

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 174.7%.

    Fiscal year ending Dec 31, 2026
    -$3.27
    EPS consensus, revenue $43.32M
    Fiscal year ending Dec 31, 2027
    -$2.70
    EPS consensus, revenue $119.01M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$3.27-$3.60 to -$2.7117$43.32M$36.87M to $100.00M17
    Dec 31, 2027-$2.70-$3.71 to $0.9217$119.01M$36.76M to $685.60M17

    Quarterly Estimates

    The EPS consensus falls from -$0.78 for the quarter ending Dec 31, 2026 to -$0.83 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.78-$0.88 to -$0.4319$17.38M$6.86M to $73.08M17
    Mar 31, 2027-$0.83-$0.94 to -$0.568$10.84M$7.00M to $17.00M7

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 7 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202616
    Fiscal year ending Dec 31, 202721
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.13.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$3.27-$3.14-$3.15-$3.16-$3.13N/A
    Fiscal year ending Dec 31, 2027-$2.70-$2.56-$2.57-$2.60-$2.56N/A
    Quarter ending Mar 31, 2027-$0.83-$0.80-$0.81-$0.85-$0.85N/A

    Frequently Asked Questions About NTLA

    What is the NTLA stock forecast?

    Consensus analyst estimates put Intellia Therapeutics's EPS at -$3.27 for the fiscal year ending Dec 31, 2026, on revenue of $43.32M. The consensus rating from 20 analysts is Hold.

    How do analysts rate NTLA stock?

    Of 20 analysts covering Intellia Therapeutics, 1 rates it Strong Buy, 9 Buy, 6 Hold, 2 Sell and 2 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from NTLA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.27, with estimates from -$3.60 to -$2.71 from 17 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.70, with estimates from -$3.71 to $0.92 from 17 analysts.

    What revenue do analysts expect from Intellia Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $43.32M, with estimates from $36.87M to $100.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $119.01M, with estimates from $36.76M to $685.60M.

    How many analysts cover NTLA?

    20 analysts rate Intellia Therapeutics stock, and 17 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.